Sample size determination in superiority clinical trials with multiple co-primary correlated endpoints.

Abstract

In pharmaceutical drug development, for regulatory purposes, there are increasing discussions on the establishment of statistically significant results demonstrating the efficacy of a new treatment on multiple co-primary endpoints. At the design stage with multiple co-primary endpoints, it is critical to determine the appropriate sample size for indicating… (More)
DOI: 10.1080/10543406.2011.551329

Topics

Cite this paper

@article{Sozu2011SampleSD, title={Sample size determination in superiority clinical trials with multiple co-primary correlated endpoints.}, author={Takashi Sozu and Tomoyuki Sugimoto and Toshimitsu Hamasaki}, journal={Journal of biopharmaceutical statistics}, year={2011}, volume={21 4}, pages={650-68} }